← Back to screener

Allogene Therapeutics, Inc. ALLO

Rank #2118 · Nasdaq · $0.4B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
33.1
P/E
-1.6
P/B
0.80
ROE
-50.3%
Op. Margin
-1241813.6%
Debt Ratio
25%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -1.6x, P/B 0.80x. Ranks in the top 53% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -50.3%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 25%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 76.8% year over year. Ranks in the top 99% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018–$-0.2B$-0.2B$0.0B––
2019–$-0.2B$-0.2B$0.0B––
2020–$-0.2B$-0.2B$-0.0B–-4438950
2021$0.0B$-0.2B$-0.2B$0.7B–21
2022$0.0B$-0.3B$-0.3B$0.6B–19
2023$0.1B$-0.2B$-0.2B$1.0B-157.911
2024$0.0B$-0.3B$-0.3B$0.7B-344986.320
2025$0.0B$-0.3B$-0.3B$0.5B-1241813.625

← See the full screener